stockrowHalozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.
- Revenue
- +39.2%
- EPS
- +45.6%
- Free cash flow
- −58.6%
- Total debt
- +115.1%
Quarter to September 2026, against a year earlier
Follow HALO
Alert me
Halozyme Therapeutics, Inc. (HALO) Return on assets
Halozyme Therapeutics, Inc.'s return on assets over the twelve months to 30 September 2026 was 17.1%, up 3.2 percentage points from fiscal 2025 (13.8%). Over the past ten years it has ranged from −46.5% (fiscal 2016) to 47.8% (fiscal 2021); the current reading is higher than 55% of that period. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 13.8% | (9.58) |
| FY2024 | 23.4% | 7.64 |
| FY2023 | 15.8% | 2.03 |
| FY2022 | 13.7% | (34.10) |
| FY2021 | 47.8% | 25.29 |
| FY2020 | 22.5% | 36.89 |
| FY2019 | −14.4% | 2.37 |
| FY2018 | −16.7% | (32.85) |
| FY2017 | 16.1% | 62.60 |
| FY2016 | −46.5% | (27.94) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ASND Ascendis Pharma A/S compare | 44.3% |
| EXEL Exelixis, Inc. compare | 33.2% |
| HALO Halozyme Therapeutics, Inc. | 17.1% |
| TECH Bio-Techne Corp compare | 7.07% |
| JAZZ Jazz Pharmaceuticals PLC compare | 1.76% |
| BMRN BioMarin Pharmaceutical Inc. compare | −0.20% |
| KYMR Kymera Therapeutics, Inc. compare | −24.4% |
| BBIO BridgeBio Pharma, Inc. compare | −37.5% |
| SMMT Summit Therapeutics PLC compare | −159.1% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on HALO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement